Nonalcoholic fatty liver disease
Conditions
Interventions
None listed
Sponsors
Department of Molecular Biochemistry & Clinical Investigation, Osaka University Graduate School of Medicine
Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University Department of Gastroenterology, JA Hiroshima General Hospital Department of Gastroenterology and Metabolism, Institute of Biomedical &
Health Sciences, Hiroshima University Division of Cardiovascular Medicine, Department of Medicine, Osaka University Graduate School of Medicine Maeda Clinic Department of Health and Nutrition Sciences,Faculty of Human Life Sciences, Nagoya Keizai University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) NAFLD patients who were diagnosed with liver biopsy within 1 year before a written informed consent. (2) Alcohol consumption (ethanol equivalent volume), <30 g/day for men, <20 g/day for women.
Exclusion criteria
Exclusion criteria: (1) History of chronic hepatic disease (viral hepatic disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis (2) Hepatocellular carcinoma and other malignant diseases (3) Patients judged inappropriate by doctor or investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the relation between the consumption of cholesterol and the liver fibrosis, steatosis, inflammation, and hepatocellular ballooning which were diagnosed with liver biopsy | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the relation between the consumption of cholesterol and AST, ALT, GTP, liver stiffness measurement, bile acid composition, and sterol oxidations | — |
Countries
Japan
Contacts
Public ContactMichihiro Iwaki
Yokohama City University Graduate School of Medicine Department of Gastroenterology and Hepatology
Outcome results
None listed